Volume 21, Number 5—May 2015
Letter
Melioidosis in Trinidad and Tobago
Table
Ref. | Site of origin (year) | Age, y/sex | Type of exposure | Concurrent condition | Clinical manifestation | Diagnostic method | Treatment (duration) | Outcome |
---|---|---|---|---|---|---|---|---|
(3) | Panama (1947) | 31/M | Fall on buttock, TR | Polio, spinal meningitis | Buttock abscess | Abscess culture | Sulfathiazole, sulfapyridine, streptomycin, penicillin | Survived |
(5) | Panama (1948) | 25/F | UNK, TR | None | Retroperitoneal abscess, sepsis | Abscess culture | Penicillin, streptomycin | Died |
(5) | Panama (1960) | 20/M | UNK | None | Acute septic arthritis | Synovial fluid culture | Chloramphenicol, novobiocin, sulfisoxazole | Survived |
(5) | Puerto Rico (1982) | 62/F | UNK | Diabetes, SLE, cirrhosis | Septic meningitis | Blood and CSF culture | Penicillin, chloramphenicol, moxalactam, amikacin | Died |
(5) | Mexico (1986) | 72/M | UNK | None | Pneumonia, splenic abscess | Blood and sputum culture | Cefoxitin, gentamicin | Died |
(5) | Martinique (1995) | 66/M | UNK, resident | Diabetes | Sepsis | Blood and urine culture | IV ceftazidime, then oral TMP/SMX and doxycycline (2 mo) | Survived |
(5) | Guadeloupe (1997) | 4/M | UNK, TR | None | Pneumonia, pleural effusion, peritonitis | Pleural fluid culture | IV ceftazidime and TMP/SMX(1 mo), then oral TMP/SMX (6 mo) | Survived |
(5) | Puerto Rico (1997) | 11/M | UNK, resident | X-linked CGD | Mediastinitis, lymphadenitis | Supraclavicular and hilar biopsy culture | Imipenem and doxycycline (6 weeks), oral cefixime and doxycycline (3 wk) | Died† |
(5) | El Salvador (2001) | UNK | UNK, TR | UNK | Cerebral abscess | UNK | UNK | Survived |
(4) | Puerto Rico (2003) | 55/F | Flood water, resident | Diabetes | Pneumonia, septic shock | Blood and sputum culture | Imipenum, amikacin, azithromycin | Died |
(6) | British Virgin Islands (2006) | 17/M | UNK, resident | CF | Pneumonia | Sputum culture, PCR | UNK | Survived |
(7) | Aruba (2009) | 7/F | UNK, TR | CF | Pneumonia | Oropharyngeal and induced sputum culture | Imipenem and ceftazidime (14 d), then inhaled meropenem (28 d) and long-term oral TMP/SMX | Survived |
(4) | Puerto Rico (2009) | 88/M | Ditch digging, resident | CAD, PVD | Pneumonia | MLST | Doxycycline (20 wk), oral TMP/SMX | Survived |
(8) | Guadeloupe (2010) | 15/F | UNK, TR | Asthma, dengue fever | Adenopathy, tumefaction | Tumefaction culture PCR | IV ceftazidime (10 d), then oral TMP/SMX (12 wk) | Survived |
(9) | Martinique (2010) | 35/M | UNK, TR | None | Diarrhea, pneumonia | Blood culture; PCR | Imipenem, G-CSF | Died |
(10) | Aruba (2012) | 46/F | Water exposure, TR | None | Breast abscesses | Abscess culture | Meropenem (14 d), then oral TMP/SMX (12 wk) | Survived |
(4) | Puerto Rico (2010) | 38/M | Landscaping, resident | None | Pneumonia, hepatitis, myocarditis, septic shock | Immunohistochemistry with polyclonal Ab; PCR | None | Died |
(4) | Puerto Rico (2012) | 60/M | Agricultural work, resident | Diabetes | Diabetic ketoacidosis | Blood culture; MLST | Amoxicillin/cloxacillin (10 d), then oral TMP/SMX (12 weeks) | Survived |
This study | Trinidad and Tobago (2014) | 17/M | Rainy season, TR | CPVT | Chronic pneumonia | BAL culture; MLST | Meropenem (2 weeks), then oral TMP/SMX (8 mo to date) | Survived |
*Ab, antibody; BAL, bronchoalveolar lavage; CAD, coronary artery disease; CGD, chronic granulomatous disease; CPVT, catecholaminergic polymorphic ventricular tachycardia; CSF, cerebrospinal fluid; G-CSF, granulocyte colony-stimulating factor; IV, intravenous; MLST, multilocus sequence typing; PVD, peripheral vascular disease; Ref., reference; SLE, systemic lupus erythematosus; TMP/SMX, trimethoprim/sulfamethoxazole; TR, travel related; UNK, unknown.
†Cause of death unknown.
References
- Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. CLSI document M45-A2. 2nd ed. Wayne (PA): The Institute; 2010.
- Godoy D, Randle G, Simpson AJ, Aanensen DM, Pitt TL, Kinoshita R, Multilocus sequence typing and evolutionary relationships among the causative agents of melioidosis and glanders, Burkholderia pseudomallei and Burkholderia mallei. J Clin Microbiol. 2003;41:2068–79. DOIPubMedGoogle Scholar
- McDowell F, Varney PL. Melioidosis, report of first case from the Western Hemisphere. J Am Med Assoc. 1947;134:361. DOIPubMedGoogle Scholar
- Doker TJ, Sharp TM, Rivera-Garcia B, Perez-Padilla J, Benoit TJ, Ellis EM, Contact investigation of melioidosis cases reveals regional endemicity in Puerto Rico. Clin Infect Dis. 2015;60:243–50. DOIPubMedGoogle Scholar
- Inglis TJ, Rolim DB, Sousa Ade Q. Melioidosis in the Americas. Am J Trop Med Hyg. 2006;75:947–54.PubMedGoogle Scholar
- Corral DM, Coates AL, Yau YC, Tellier R, Glass M, Jones SM, Burkholderia pseudomallei infection in a cystic fibrosis patient from the Caribbean: a case report. Can Respir J. 2008;15:237–9.PubMedGoogle Scholar
- O’Sullivan BP, Torres B, Conidi G, Smole S, Gauthier C, Stauffer KE, Burkholderia pseudomallei infection in a child with cystic fibrosis: acquisition in the Western Hemisphere. Chest. 2011;140:239–42. DOIPubMedGoogle Scholar
- Meckenstock R, Therby A, Marque-Juillet S, Monnier S, Khau D, Pangon B, Cutaneous melioidosis in adolescent returning from Guadeloupe. Emerg Infect Dis. 2012;18:359–60. DOIPubMedGoogle Scholar
- Gétaz L, Abbas M, Loutan L, Schrenzel J, Iten A, Simon F, Fatal acute melioidosis in a tourist returning from Martinique Island, November 2010. Euro Surveill. 2011;16:19758.PubMedGoogle Scholar
- Mickail N, Klein NC, Cunha BA, Schoch PA. Melioidosis breast abscesses. J Infect. 2012;64:434–5. DOIPubMedGoogle Scholar
Page created: April 17, 2015
Page updated: April 17, 2015
Page reviewed: April 17, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.